These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 27149990)

  • 1. Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers.
    Pfefferle AD; Agrawal YN; Koboldt DC; Kanchi KL; Herschkowitz JI; Mardis ER; Rosen JM; Perou CM
    Dis Model Mech; 2016 Jul; 9(7):749-57. PubMed ID: 27149990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells.
    Herschkowitz JI; Zhao W; Zhang M; Usary J; Murrow G; Edwards D; Knezevic J; Greene SB; Darr D; Troester MA; Hilsenbeck SG; Medina D; Perou CM; Rosen JM
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2778-83. PubMed ID: 21633010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
    Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
    Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Claudin-low-like mouse mammary tumors show distinct transcriptomic patterns uncoupled from genomic drivers.
    Fougner C; Bergholtz H; Kuiper R; Norum JH; Sørlie T
    Breast Cancer Res; 2019 Jul; 21(1):85. PubMed ID: 31366361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer.
    Knight JF; Lesurf R; Zhao H; Pinnaduwage D; Davis RR; Saleh SM; Zuo D; Naujokas MA; Chughtai N; Herschkowitz JI; Prat A; Mulligan AM; Muller WJ; Cardiff RD; Gregg JP; Andrulis IL; Hallett MT; Park M
    Proc Natl Acad Sci U S A; 2013 Apr; 110(14):E1301-10. PubMed ID: 23509284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-exome DNA sequence analysis of Brca2- and Trp53-deficient mouse mammary gland tumours.
    Francis JC; Melchor L; Campbell J; Kendrick H; Wei W; Armisen-Garrido J; Assiotis I; Chen L; Kozarewa I; Fenwick K; Swain A; Smalley MJ; Lord CJ; Ashworth A
    J Pathol; 2015 Jun; 236(2):186-200. PubMed ID: 25692405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer.
    Liu X; Holstege H; van der Gulden H; Treur-Mulder M; Zevenhoven J; Velds A; Kerkhoven RM; van Vliet MH; Wessels LF; Peterse JL; Berns A; Jonkers J
    Proc Natl Acad Sci U S A; 2007 Jul; 104(29):12111-6. PubMed ID: 17626182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer.
    Silva GO; He X; Parker JS; Gatza ML; Carey LA; Hou JP; Moulder SL; Marcom PK; Ma J; Rosen JM; Perou CM
    Breast Cancer Res Treat; 2015 Jul; 152(2):347-56. PubMed ID: 26109346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer.
    Weaver Z; Montagna C; Xu X; Howard T; Gadina M; Brodie SG; Deng CX; Ried T
    Oncogene; 2002 Aug; 21(33):5097-107. PubMed ID: 12140760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rad51c- and Trp53-double-mutant mouse model reveals common features of homologous recombination-deficient breast cancers.
    Tumiati M; Munne PM; Edgren H; Eldfors S; Hemmes A; Kuznetsov SG
    Oncogene; 2016 Sep; 35(35):4601-10. PubMed ID: 26820992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer.
    Johnstone CN; Smith YE; Cao Y; Burrows AD; Cross RS; Ling X; Redvers RP; Doherty JP; Eckhardt BL; Natoli AL; Restall CM; Lucas E; Pearson HB; Deb S; Britt KL; Rizzitelli A; Li J; Harmey JH; Pouliot N; Anderson RL
    Dis Model Mech; 2015 Mar; 8(3):237-51. PubMed ID: 25633981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer.
    Annunziato S; de Ruiter JR; Henneman L; Brambillasca CS; Lutz C; Vaillant F; Ferrante F; Drenth AP; van der Burg E; Siteur B; van Gerwen B; de Bruijn R; van Miltenburg MH; Huijbers IJ; van de Ven M; Visvader JE; Lindeman GJ; Wessels LFA; Jonkers J
    Nat Commun; 2019 Jan; 10(1):397. PubMed ID: 30674894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathways contributing to development of spontaneous mammary tumors in BALB/c-Trp53+/- mice.
    Yan H; Blackburn AC; McLary SC; Tao L; Roberts AL; Xavier EA; Dickinson ES; Seo JH; Arenas RB; Otis CN; Cao QJ; Lawlor RG; Osborne BA; Kittrell FS; Medina D; Jerry DJ
    Am J Pathol; 2010 Mar; 176(3):1421-32. PubMed ID: 20110418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Chromatin Remodeling Component Arid1a Is a Suppressor of Spontaneous Mammary Tumors in Mice.
    Kartha N; Shen L; Maskin C; Wallace M; Schimenti JC
    Genetics; 2016 Aug; 203(4):1601-11. PubMed ID: 27280691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome.
    Kuperwasser C; Hurlbut GD; Kittrell FS; Dickinson ES; Laucirica R; Medina D; Naber SP; Jerry DJ
    Am J Pathol; 2000 Dec; 157(6):2151-9. PubMed ID: 11106587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts.
    Pfefferle AD; Herschkowitz JI; Usary J; Harrell JC; Spike BT; Adams JR; Torres-Arzayus MI; Brown M; Egan SE; Wahl GM; Rosen JM; Perou CM
    Genome Biol; 2013 Nov; 14(11):R125. PubMed ID: 24220145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 in breast cancer subtypes and new insights into response to chemotherapy.
    Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
    Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 controls the plasticity of mammary luminal progenitor cells downstream of Met signaling.
    Chiche A; Di-Cicco A; Sesma-Sanz L; Bresson L; de la Grange P; Glukhova MA; Faraldo MM; Deugnier MA
    Breast Cancer Res; 2019 Jan; 21(1):13. PubMed ID: 30683141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic Trp53 mutations differentially drive breast cancer and evolution of metastases.
    Zhang Y; Xiong S; Liu B; Pant V; Celii F; Chau G; Elizondo-Fraire AC; Yang P; You MJ; El-Naggar AK; Navin NE; Lozano G
    Nat Commun; 2018 Sep; 9(1):3953. PubMed ID: 30262850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mouse Models of Breast Cancer Share Amplification and Deletion Events with Human Breast Cancer.
    Rennhack J; To B; Wermuth H; Andrechek ER
    J Mammary Gland Biol Neoplasia; 2017 Mar; 22(1):71-84. PubMed ID: 28124185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.